Paratek Pharmaceuticals, Inc saw its loss widen to $23.63 million, or $1.04 a share for the quarter ended Sep. 30, 2016. In the previous year period, the company reported a loss of $23.42 million, or $1.33 a share. The company has not recorded any revenues for the current as well as previous quarter.
Operating loss for the quarter was $23.11 million, compared with an operating loss of $23.37 million in the previous year period.
"With the continued progress we have made this quarter, we remain on track to file our NDA for both community-acquired skin and pneumonia indications in the first half of 2018," said Michael Bigham, Chairman and Chief Executive Officer, Paratek. “Importantly, the promising data from our Phase 1b study in UTI support developing a registration pathway for omadacycline in UTI, the most common community-acquired bacterial infection. In addition to the clinical progress this quarter, we also completed important regulatory requirements that will support our planned NDA. We are pleased with the progress we have made to date, and remain excited about the eventful year ahead."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: editor@irisindia.net
